French drugmaker Ipsen (Euronext: IPN) has secured a positive reimbursement decision from the UK’s National Institute for Health and Care Excellence (NICE).
The decision means that Cabometyx (cabozantinib), in combination with Opdivo (nivolumab), will be funded for the first-line treatment of certain people with advanced renal cell carcinoma.
The NICE reached its verdict on the basis of data from a study showing that the risk of death was decreased by 34% with cabozantinib in combination with nivolumab, compared to a currently available therapy, sunitinib.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze